High Calcium Intake Associated With Reduced Colorectal Adenoma Risk in Certain Individuals
- Prior studies associating calcium intake and colorectal adenoma risk have been inconsistent.
- Variations in two specific genes were shown to modify the association.
- Genetic tests may help determine which patients would benefit from higher calcium intake.
WASHINGTON, D.C. — Researchers have identified a potential explanation for inconsistent results from prior research about the association between calcium intake and risk for colorectal adenomas, which are precursors to colorectal cancers. The findings may help identify patients who would benefit from higher calcium intake or calcium supplementation, according to the researcher who presented the data at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.
Previous studies suggested that a high intake of calcium was associated with a reduced risk for colorectal adenomas and cancer, but data from the Women’s Health Initiative did not support the benefit for colorectal cancer after seven years of follow-up, according to Xiangzhu Zhu, M.D., M.P.H., staff scientist in the Division of Epidemiology in the Department of Medicine at Vanderbilt-Ingram Cancer Center and Vanderbilt University School of Medicine in Nashville, Tenn.
Zhu and colleagues conducted a two-phase study to investigate whether the associations between risk for colorectal adenoma and intake of calcium and magnesium, as well as the calcium/magnesium ratio, were modified by common changes in 14 genes involved in controlling the amounts of calcium and magnesium in the body.
They evaluated 1,818 cases and 3,992 controls from the Tennessee Colorectal Polyp Study, a colonoscopy-based case-control study conducted in Nashville. Patients with the highest calcium intake showed no reduction in their risk for colorectal adenoma if they had no changes in either of two of the 14 genes analyzed, the KCNJ1 and SLC12A1 genes, both of which were identified and replicated in the two-phase study and are essential in calcium reabsorption in the kidney.
Fifty-two percent of the study population carried genetic changes in at least one of the two genes, and 13 percent of the population carried genetic changes in both genes. The highest calcium intake — patients in the top 33 percent — was significantly related to a 39 percent reduction in adenoma risk for patients who carried a genetic change in one gene and a 69 percent reduction in adenoma risk among those who carried genetic changes in both genes, according to Zhu. In addition, the corresponding reduction in risk for advanced or multiple adenomas was 89 percent among those with genetic changes in both genes.
According to Zhu, based on these data, a person with genetic changes in any of the two genes will see an increased risk for adenoma if they consume less than about 1,000 mg of calcium a day, especially if they carry genetic changes in both genes. The risk will increase by more than 50 percent for an adenoma and by 120 percent for advanced or multiple adenomas. “These patients should increase their calcium intake to reduce the risks,” Zhu said.
“Our results may provide one possible explanation for the inconsistency in previous studies on calcium intake and colorectal abnormalities because calcium may primarily prevent colorectal cancer in the early stage and reduce risk only among those with genetic changes in calcium reabsorption, which involves KCNJ1 and SLC12A1,” Zhu said. “If confirmed in future studies, our findings will be critical for the development of new personalized prevention strategies for colorectal cancer.”
The study was funded by National Institutes of Health (National Center for Complementary and Alternative Medicine/Office of Dietary Supplements) Grant Number 5R01AT004660-04 (PI: Qi Dai). The project was conducted using resources collected from the Tennessee Colorectal Polyp Study, a project of the Vanderbilt Gastrointestinal Cancer Specialized Program of Research Excellence.
Press registration for the AACR Annual Meeting 2013 is free to qualified journalists and public information officers.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.
In Washington, D.C.,
April 6-10, 2013: